Group 1 - The innovative drug sector in the A-share market has experienced a decline [1] - Yuan Dong Biological has dropped over 8% [1] - Sunshine Novo has decreased by more than 6% [1] Group 2 - Hai Te Biological and Guangsheng Tang have both fallen over 5% [1] - Yi Fang Biological, Li Fang Pharmaceutical, Kang Chen Pharmaceutical, Ang Li Kang, and Ou Lin Biological have all seen declines of over 4% [1]

Core Viewpoint - On August 25, 2023, brokerage firms provided target prices for listed companies, with notable increases in target prices for companies in the agriculture, coal mining, and construction materials sectors, indicating potential investment opportunities in these industries [1][2]. Target Price Increases - The companies with the highest target price increases were: - Longping High-Tech (隆平高科) with a target price increase of 38.75% to 14.00 CNY [2] - Xinji Energy (新集能源) with a target price increase of 37.40% to 9.00 CNY [2] - Beixin Building Materials (北新建材) with a target price increase of 36.57% to 36.90 CNY [2] Brokerage Recommendations - A total of 163 listed companies received brokerage recommendations on August 25, with notable mentions: - Shede Liquor (舍得酒业) received 4 recommendations [4] - Shuiyang Co. (水羊股份) and Marubi Biotechnology (丸美生物) each received 3 recommendations [4] Rating Adjustments - One company had its rating upgraded: - Guodian Power (国电电力) was upgraded from "Hold" to "Buy" by Huayuan Securities [5] - Three companies had their ratings downgraded: - Minhe Livestock (民和股份) from "Buy" to "Hold" [6] - Chifeng Gold (赤峰黄金) from "Buy" to "Hold" [6] - Silan Microelectronics (士兰微) from "Buy" to "Hold" [6] First-Time Coverage - Seven companies received first-time coverage with positive ratings: - Ganhua Science and Technology (甘化科工) received a "Buy" rating from Dongwu Securities [7] - Wangneng Environment (旺能环境) received a "Buy" rating from Xinda Securities [7] - Yingliu Co. (应流股份) received an "Increase" rating from Shanxi Securities [7] - New Clean Energy (新洁能) received an "Increase" rating from Industrial Securities [7] - Weijian Medical (稳健医疗) received a "Buy" rating from Northeast Securities [7]

Group 1 - The latest stock price of Yifang Biotech-U is 42.18 yuan, up 0.55% from the previous trading day, with an intraday high of 43.79 yuan and a low of 41.75 yuan, and a trading volume of 554 million yuan [1] - The company operates in the biopharmaceutical industry, focusing on innovative drug development, with 2 products already on the market, 1 in the registration clinical trial phase, 2 in Phase II clinical trials, and several preclinical projects [1] - The company reported a revenue of 19.16 million yuan for the first half of 2025, representing a year-on-year growth of 28.85% [1] Group 2 - The company has applied for 37 new invention patents recently, with a total of 138 invention patents authorized domestically and internationally [1] - The company announced plans to use no more than 1 billion yuan of idle raised funds for cash management, aimed at purchasing safe and liquid financial products [1] - On August 25, the net inflow of main funds was 46.54 million yuan, with a cumulative net inflow of 112.73 million yuan over the past five days [1]

天眼查商业履历信息显示，益方生物科技(上海)股份有限公司，成立于2013年，位于上海市，是一家以 从事医药制造业为主的企业。企业注册资本57832.7844万人民币，实缴资本46000万人民币。公司法定 代表人为YAO LIN WANG（王耀林）。 通过天眼查大数据分析，益方生物科技(上海)股份有限公司共对外投资了1家企业，参与招投标项目9 次，知识产权方面有商标信息19条，专利信息59条，此外企业还拥有行政许可18个。 来源：金融界 金融界消息 截至2025年8月25日收盘，益方生物U（688382）报收于42.18元，上涨0.55%，换手率 3.11%，成交量12.98万手，成交金额5.54亿元。 资金流向方面，今日主力资金净流入4654.46万元，占比成交额8.4%。其中，超大单净流入1398.05万 元、占成交额2.52%，大单净流入3256.41万元、占成交额5.88%，中单净流出流入1876.94万元、占成交 额3.39%，小单净流出6531.40万元、占成交额11.79%。 益方生物最新一期业绩显示，截至2025中报，公司营业总收入1916.38万元、同比增长28.85%，归属净 利润11943 ...

金融界2025年8月24日消息，汇添富医疗服务灵活配置混合C(015121) 最新净值1.9690元，该基金近一周 收益率0.66%，近3个月收益率24.86%，今年来收益率66.44%。 汇添富医疗服务灵活配置混合C基金成立于2022年2月14日，基金经理张韡，截至2025年6月30日，汇添 富医疗服务灵活配置混合C规模10.69亿元。 该基金股票持仓前十分别为：恒瑞医药、科伦药业、海思科、百利天恒、新诺威、泽璟制药-U、信立 泰、热景生物、益方生物-U、诺诚健华-U。前十持仓占比合计68.66%。 来源：金融界 ...

Core Viewpoint - The company Yifang Biotechnology (Shanghai) Co., Ltd. has approved the use of up to RMB 1 billion of temporarily idle raised funds for cash management to enhance fund utilization efficiency and increase returns for shareholders [1][2][4]. Fundraising Basic Situation - The company was approved to publicly issue 115 million shares at a price of RMB 18.12 per share, raising a total of RMB 2,083.8 million, with a net amount of approximately RMB 1,982.15 million after deducting related issuance costs [2]. Cash Management Details - The purpose of cash management is to improve the efficiency of raised fund usage while ensuring project construction and fund safety. The company plans to invest in high-security, liquid, and principal-protected financial products or deposit products, with a maximum investment period of 12 months [2]. - The decision is valid for 12 months from the date of board approval, and the funds can be used in a rolling manner [2]. Review Procedures and Risk Control - The company has established a robust approval and execution process for cash management, including measures such as using a special account, board authorization for operational decisions, and supervision by independent directors and internal audit departments [3]. - Despite choosing low-risk products, market fluctuations may still impact investments, and the company will ensure that funds are returned to the special account or rolled over upon maturity [3]. Impact on the Company and Sponsor Opinions - The cash management will not affect the company's daily cash flow, project construction progress, or main business development, while also improving fund utilization efficiency and overall performance [4]. - The sponsor institution has confirmed that the necessary decision-making procedures have been followed, and the action complies with relevant laws and regulations, with no objections raised regarding the matter [4].

外资态度来看，本期较上一季度持股减少的外资基金共计3个，包括ABA-Bio (Hong Kong) Limited、 LAV Apex Hong Kong Limited、OAP III (HK) Limited，持股减少占比达2.40%。本期较上一季未再披露 的外资机构即LAV Alpha Hong Kong Limited。 2025年8月23日，益方生物(688382.SH)发布2025年半年度报告。截至2025年8月22日，共有142个机构投 资者披露持有益方生物A股股份，合计持股量达3.51亿股，占益方生物总股本的60.69%。其中，前十大 机构投资者包括InventisBio Hong Kong Limited、YUEHENG JIANG LLC、ABA-Bio (Hong Kong) Limited、XING DAI LLC、OAP III (HK) Limited、LAV Apex Hong Kong Limited、中国建设银行股份有 限公司-汇添富创新医药主题混合型证券投资基金、中国工商银行股份有限公司-中欧医疗健康混合型证 券投资基金、香港中央结算有限公司、招商银行股份有限公司-睿远成长 ...

格隆汇8月22日丨益方生物(688382.SH)公布2025年半年报，公司营业收入为1916万元，同比上升 28.8%；归母净利润自去年同期亏损2.14亿元变为亏损1.19亿元，亏损额有所减少；扣非归母净利润自 去年同期亏损2.15亿元变为亏损1.29亿元，亏损额有所减少。 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-035 益方生物科技（上海）股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第一次临时股东会 召开日期时间：2025 年 9 月 8 日 9 点 30 分 召开地点：上海市浦东新区张衡路 1000 弄 63 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 8 日 至2025 年 9 月 8 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东会召开日期：2025年9月8日 本次股东会 ...

一、董事会会议召开情况 证券代码：688382 证券简称：益方生物 公告编号：2025-034 益方生物科技（上海）股份有限公司 第二届董事会 2025 年第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、董事会会议审议情况 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）及 指定媒体的《益方生物关于 2022 年限制性股票激励计划预留授予部分第二个归 属期符合归属条件的公告》（公告编号：2025-030）。 本议案已经董事会薪酬与考核委员会审议通过。 表决结果：同意 9 票；反对 0 票；弃权 0 票。 益方生物科技（上海）股份有限公司（以下简称"公司"）第二届董事会 2025 年第五次会议于 2025 年 8 月 21 日以现场结合通讯形式召开，本次会议通 知已于 2025 年 8 月 16 日以书面形式发出。会议应出席董事 9 名，实际出席董 事 9 名，公司高级管理人员列席本次会议。本次会议的召集、召开程序符合 《中华人民共和国公司法》及《益方生物科技（上海）股份有 ...